开始前列腺特异性抗原检测时年龄较轻与前列腺癌死亡率下降幅度更大相关:哥德堡随机人群前列腺癌筛查试验24年随访
哥德堡-1随机试验纳入2万名男性,随机分为每两年一次PSA筛查组(n=10000)或不邀请但可机会性检测的对照组(n=10000),随访24年。开始PSA检测年龄较轻与前列腺癌死亡率下降幅度更大相关,55岁开始筛查较60岁开始约减半前列腺癌死亡风险;全队列起始年龄与筛查效果交互作用检验p=0.052,仅参加筛查者中p=0.002。
要点
- 开始PSA检测年龄较轻与前列腺癌死亡率下降幅度更大相关。
- 55岁开始筛查较60岁开始首次PSA约减半前列腺癌死亡风险。
- 起始年龄与筛查效果交互作用全队列p=0.052,参加筛查者p=0.002。
核心结论
- 鉴于既往筛查试验纳入开始筛查时年龄高达70岁的男性,本研究结果提示既往试验报告的效应量低估了当前推荐50-55岁开始筛查项目的效果。
- 作者建议PSA筛查应不晚于55岁开始。
研究设计与样本
- 哥德堡-1随机试验邀请男性在50至70岁之间每两年进行一次PSA筛查(筛查组n=10000)或不邀请但暴露于机会性PSA检测(对照组n=10000)。
- 在三种设定中建模起始年龄与前列腺癌死亡率绝对风险下降之间的非线性关联:意向筛查(随机分组)、历史对照(筛查组与1990-1994年登记数据)、仅参加筛查者(筛查参加者与匹配对照)。
- 通过比较含或不含试验组与年龄交互作用的生存模型,检验筛查对前列腺癌死亡率的效果是否取决于开始筛查年龄(意向筛查和仅参加筛查者)。
主要发现
- 开始PSA检测年龄较轻与前列腺癌死亡率下降幅度更大相关。
- 55岁开始筛查较60岁首次PSA约减半前列腺癌死亡风险。
- 起始年龄与筛查对前列腺癌死亡率效果的关联检验在全队列中略高于常规统计学显著性水平(p=0.052),在参加筛查者中具有统计学显著性(p=0.002)。
临床怎么用
- 作者建议PSA筛查应不晚于55岁开始。
局限性
- 55岁前开始筛查的男性疾病特异性死亡数量少。
- 难以区分开始筛查年龄与筛查持续时间的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of death from prostate cancer (PC) depends on age, but the age at which to start prostate-specific antigen (PSA) screening remains uncertain. OBJECTIVE: To study the relationship between risk reduction for PC mortality and age at first PSA screening. DESIGN, SETTING, AND PARTICIPANTS: The randomized Göteborg-1 trial invited men for biennial PSA screening between the ages of 50 and 70 yr (screening, n = 10 000) or no invitation but exposure to opportunistic PSA testing (control, n = 10 000). INTERVENTION: Regular versus opportunistic PSA screening or no PSA. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We modeled the nonlinear association between starting age and the absolute risk reduction in PC mortality in three settings: (1) intention-to-screen (randomized arms); (2) historical control (screening group and 1990-1994 registry data); and (3) attendees only (screening attendees and matched controls). We tested whether the effect of screening on PC mortality depends on the age at starting screening by comparing survival models with and without an interaction between trial arm and age (intention-to-screen and attendees only). RESULTS AND LIMITATIONS: Younger age on starting PSA testing was associated with a greater reduction in PC mortality. Starting screening at age 55 yr approximately halved the risk of PC death compared to first PSA at age 60 yr. The test of association between starting age and the effect of screening on PC mortality was slightly greater than the conventional level of statistical significance (p = 0.052) for the entire cohort, and statistically significant among attendees (p = 0.002). This study is limited by the low number of disease-specific deaths for men starting screening before age 55 yr and the difficulty in discriminating between the effect of starting age and screening duration. CONCLUSIONS: Given that prior screening trials included men aged up to 70 yr on starting screening, our results suggest that the effect size reported in prior trials underestimates that of currently recommended programs starting at age 50-55 yr. PATIENT SUMMARY: In this study from the Göteborg-1 trial, we looked at the effect of prostate-specific antigen (PSA) screening in reducing men's risk of dying from prostate cancer given the age at which they begin testing. Starting at a younger age reduced the risk of prostate cancer death by a greater amount. We recommend that PSA screening should start no later than at age 55 yr.
引用
- Carlsson SV, Arnsrud Godtman R, Pihl CG, et al. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial. Eur Urol. 2022. PMID: 36334968. doi:10.1016/j.eururo.2022.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。